FDA Modernization Act 3.0
Amendments propose changes to this bill. Members vote on amendments separately before the final bill vote. An agreed amendment becomes part of the bill; a failed amendment does not.
1 agreed to
| Amendment | Sponsor | Status |
|---|---|---|
| SAMDT 3,328 | Booker, Cory A. | Agreed to |
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
FDA Modernization Act 3.0
This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug.
The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications, and may make other changes to the regulations as appropriate.
The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule.
Held at the desk.
- Engrossed in Senate Formatted Text PDF Formatted XML
- Introduced in Senate Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). S. 5046: FDA Modernization Act 3.0. 118th Congress. Open America. https://openamerica.io/bill/118-S-5046/
"S. 5046: FDA Modernization Act 3.0." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-S-5046/.
S. 5046, 118th Cong. (2026), https://openamerica.io/bill/118-S-5046/.
[S. 5046: FDA Modernization Act 3.0](https://openamerica.io/bill/118-S-5046/)